Facebook
X
LinkedIn
Forward
Spotlight on Desmoid Tumors: Bridging Knowledge Gaps for Optimal Patient Care
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 70 Minutes
Overview
Watch this certified, on-demand webcast of a live dinner program to gain expert insights into the evolving treatment landscape for desmoid tumors. In an engaging discussion format, Candace Haddox, MD and David Shulman, MD, explore key aspects of desmoid tumor management—including disease pathogenesis, diagnosis, treatment selection, and adverse event management—through patient case discussions and review of the latest clinical data.
Learning Objectives
- Describe evidence-based strategies for the diagnosis of desmoid tumors, including molecular profiling, imaging modalities, and the role of multidisciplinary team consultation.
- Discuss the efficacy, safety, and expected outcomes of standard-of-care therapies with patients under active surveillance considering systemic treatment.
- Develop individualized treatment plans for patients with progressive, unresectable, recurrent, or refractory desmoid tumors based on available clinical data, clinical guidelines, and patient-specific factors.
- Manage treatment-related adverse events associated with systemic therapies.
Target Audience:
This activity is designed to educate oncology physicians as well as advanced practice providers, physician assistants, pharmacists, and nurse specialists involved in the care of patients with desmoid tumors.
This educational activity is supported by a medical education grant from SpringWorks Therapeutics, Inc.
Presented By
Faculty
Candace Haddox, MD,
Physician
Dana Farber Cancer Institute
Instructor of Medicine
Harvard Medical School
Boston, MA
Candace Haddox, MD, is an Instructor in Medicine at Harvard Medical School, and a medical oncologist and clinical/translational investigator in the Sarcoma Center and the Center for Cancer Therapeutic Innovation at Dana-Farber Cancer Institute. Dr. Haddox's research focuses on developing novel therapies rooted in sarcoma biology and determining mechanisms of treatment response and resistance.
Dr. Haddox received her Bachelor of Science in neurobiology from the University of Miami. She completed a post-baccalaureate research fellowship at the National Institutes of Health and received her Medical Degree from the University of South Florida. Dr. Haddox completed a residency in Internal Medicine at the Mayo Clinic in Rochester, Minnesota, and a fellowship in Medical Oncology at Duke University, where she also served as Chief Fellow. She joined the faculty at Dana-Farber Cancer Institute in 2021, where she currently sees patients with sarcomas and leads clinical trials in early drug development.
David Shulman, MD,
Attending Physician
Dana-Farber Cancer Institute
Boston Children’s Cancer
Assistant Professor of Pediatrics
Harvard Medical School
Boston, MA
David Shulman, MD, is a Pediatric Oncologist and clinical/translational researcher at Dana-Farber Cancer Institute, and an Assistant Professor of Pediatrics at Harvard Medical School. He is the director of the DFCI AYA Sarcoma Program. His NIH-funded research program is dedicated to improving outcomes for adolescents and young adults (AYA) with sarcomas through investigation of novel approaches to therapy and circulating tumor DNA (ctDNA) as a clinical biomarker. David's clinical focus is on the care of AYAs with sarcomas.
Disclosures:
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Candace Haddox, MD, discloses advisory boards with Springworks Therapeutics and Deciphera but these relationships have ended; consulting fees with Aadi and Biosciences; and contracted research with Cogent Biosciences, Tubulis Gmbh, HifiBio Therapeutics, Tango Therapeutics, Aadi Biosciences and Merck KGaA/EMD-Serono, during the past 24 months.
David Shulman, MD, discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.
Other Contributors:
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients
Available Credit
- 1.00 AMA PRA Category 1 Credit™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Price
Required Hardware/software
Access to internet required
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above